Winchester, MA, United States of America

Feng Li

This inventor holds 14 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Ariad Pharmaceuticals, Inc., Merck Sharp + Dohme Corp., Takeda Pharmaceutical Company Limited. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Feng Li. Retrieved from https://idiyas.com/inventor/feng-li-86e5gx68

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 12)

% Patents Active = 78.6

CIPO Patents = 4 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 55(Granted Patents)

Location History:

Dresher, PA (US) (2017 - 2020)
Cambridge, MA (US) (2021 - 2023)
Winchester, MA (US) (2014 - 2024)

Company Filing History:

11 out of 69

Ariad Pharmaceuticals, Inc.

patents

2 out of 2,405

Merck Sharp + Dohme Corp.

patents

1 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2014-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11958850 - Heteroaryl compounds for kinase inhibition (2024-04-16),

2. 11753404 - Aminothiazole compounds as c-Kit inhibitors (2023-09-12),

3. 11117883 - Benzimidazole compounds as c-Kit inhibitors (2021-09-14),

4. 11001580 - Aminothiazole compounds as c-Kit inhibitors (2021-05-11),

5. 10772888 - Solid pharmaceutical compositions containing an integrase inhibitor (2020-09-15),

6. 10227342 - Heteroaryl compounds for kinase inhibition (2019-03-12),

7. 9834521 - Choline kinase inhibitors (2017-12-05),

8. 9796712 - Heteroaryl compounds for kinase inhibition (2017-10-24),

9. 9649311 - Solid pharmaceutical compositions containing an integrase inhibitor (2017-05-16),

10. 9573934 - Methods and compositions for the synthesis of multimerizing agents (2017-02-21),

11. 9273077 - Phosphorus derivatives as kinase inhibitors (2016-03-01),

12. 9024028 - Methods and compositions for the synthesis of multimerizing agents (2015-05-05),

13. 9012462 - Phosphorous derivatives as kinase inhibitors (2015-04-21),

14. 8912330 - Azaindole derivatives as kinase inhibitors (2014-12-16),

Title: The Innovative Contributions of Feng Li

Introduction

Feng Li is a prominent inventor based in Winchester, MA (US), known for his significant contributions to the field of pharmaceutical sciences. With a total of 14 patents to his name, he has made remarkable advancements in the development of compounds that target specific kinase activities.

Latest Patents

Feng Li's latest patents include groundbreaking work on heteroaryl compounds for kinase inhibition. These compounds and pharmaceutical compositions are designed to modulate kinase activity, particularly focusing on mutant EGFR and mutant HER2 kinase activity. Additionally, he has developed aminothiazole compounds as c-Kit inhibitors, which are useful in treating cancers and other diseases mediated by serine-threonine kinases.

Career Highlights

Throughout his career, Feng Li has worked with notable companies such as Ariad Pharmaceuticals, Inc. and Merck Sharp & Dohme Corporation. His work in these organizations has contributed to the advancement of cancer therapies and other medical treatments.

Collaborations

Feng Li has collaborated with esteemed colleagues, including William C. Shakespeare and Xiaotian Zhu, further enhancing the impact of his research and innovations.

Conclusion

Feng Li's contributions to the field of pharmaceutical sciences through his innovative patents and collaborations have made a significant impact on cancer treatment and kinase inhibition. His work continues to inspire advancements in medical research and development.

Profile summary based on public USPTO records.